摘要
目的:探讨培美曲塞二钠联合顺铂治疗晚期肺腺癌的疗效及对血清细胞角质素片段抗原21-1(CYFRA21-1)、糖类抗原125(CA125)、癌胚抗原(CEA)的影响。方法:选择2014年5月至2017年5月于我院进行治疗的晚期肺腺癌患者90例,随机分为观察组(n=50)和对照组(n=40)。观察组采用培美曲塞二钠联合顺铂进行治疗;对照组采用紫杉醇联合顺铂治疗。比较两组患者的临床疗效、CEA、CA125、CYFRA21-1、神经元特异性烯醇化酶(NSE)及两组患者不良反应发生情况。结果:观察组患者治疗后有效率为72.00%,显著高于对照组的42.50%(P<0.05);治疗前,两组患者血清CYFRA21-1、CA125、CEA水平无明显差异,治疗后,两组患者血清CYFRA21-1、CA125、CEA水平均有所下降(P<0.05);且观察组患者血清CYFRA21-1、CA125、CEA水平均低于对照组(P<0.05);治疗前,两组患者血清NSE水平无明显差异,治疗后,两组患者血清NSE水平有所下降(P<0.05);且观察组患者血清NSE水平低于对照组(P<0.05);治疗期间,观察组患者不良反应发生率均明显低于对照组(P<0.05)。结论:培美曲塞二钠联合顺铂治疗晚期肺腺癌患者的疗效较高,可有效改善患者血清CYFRA21-1、CA125、CEA水平,不良反应较少,且患者基本可以耐受,值得推广应用。
Objective: To study curative efficacy of permetazole sodium combined with cisplatin in treatment of advanced lung adenocarcinoma and its effectson serum cytokine fragment antigen 21-1 (cyfra21-1), carbohydrate antigen 125 (CA125), carcinoembryonic antigen (CEA). Methods: 90 patients with advanced lung adenocarcinoma from May 2014 to May 2017 for research, they were randomly divided into observation group (n=50) and control group (n=40). The observation group was treated with the combination of permetazole and cisplatin. The control group was treated with paclitaxel combined with cisplatin. Clinical efficacy, CEA, CA125, cyfra21-1, neuron-specific enolase (NSE) and adverse reactions were compared between the two groups. Results: After treatment, the effective rate of the observation group was 72.00% after treatment, which was significantly higher than 42.50% of the control group (P<0.05). Before treatment, there was no significant difference in the serum cyfra21-1, CA125 and CEA levels between the two groups. After treatment, the serum cyfra21-1, CA125 and CEA levels of both groups decreased (P<0.05). The serum cyfra21-1, CA125 and CEA levels of the observation group were all lower than those of the control group (P<0.05). Before treatment, there was no significant difference in serum NSE level between the two groups. After treatment, serum NSE level decreased (P<0.05). The serum NSE level of the observation group was lower than that of the control group (P<0.05). During the treatment, the adverse reaction rate of the observation group was significantly lower than that of the control group (P<0.05). Conclusion: Patients with advanced lung adenocarcinoma treated by pmetraxer disodium combined with cisplatin have higher efficacy, which can effectively improve the levels of cyfra21-1, CA125 and CEA in serum of patients with less adverse reactions, and the patients are basically tolerable and worthy of popularization and application.
作者
罗娟
李嵘
黄春梅
方霖
LUO Juan;LI Rong;HUANG Chunmei(Meishan People's Hospital, Sichuan Meishan 620010, China)
出处
《河北医学》
CAS
2019年第5期747-751,共5页
Hebei Medicine
基金
四川省自然科学基金资助项目,(编号:21030193)
关键词
晚期肺腺癌
培美曲塞二钠
顺铂
细胞角质素片段抗原21-1
糖类抗原125
癌胚抗原
Advanced lung adenocarcinoma
Pemetazole disodium
Cisplatin
Cytokine fragment antigen 21-1
Carbohydrate antigen 125
Carcinoembryonic antigen
